Lacosamida Zentiva

Lacosamide, the active ingredient in Lacosamida Zentiva, is a sodium channel blocker presented as an oral tablet for oral use. It is employed as adjunctive therapy for partial‑onset seizures in patients with epilepsy. The medication works by stabilizing neuronal membranes and reducing hyperexcitability.

GNH USA supplies Lacosamida Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring reliable quality and regulatory compliance across global markets.

Lacosamide is used in the management of epilepsy, specifically targeting the partial‑onset seizure pathway.

- Partial‑onset seizures: reduces seizure frequency when added to existing antiepileptic therapy. - Refractory epilepsy: provides additional seizure control for patients not fully responsive to other drugs. - Adjunctive therapy in epilepsy: enhances overall seizure management as part of a combination regimen.

Lacosamide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness: transient sensation of light‑headedness. - Headache: mild to moderate intensity. - Nausea: occasional stomach upset. - Fatigue: feeling of tiredness. - Diplopia: double vision. - Blurred vision: visual disturbances.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome: severe skin reaction requiring immediate medical attention. - Toxic epidermal necrolysis: life‑threatening skin detachment. - Cardiac conduction abnormalities: PR‑interval prolongation or arrhythmia. - Suicidal ideation: emergent thoughts of self‑harm. - Severe hepatic injury: marked liver enzyme elevation. - Anaphylaxis: acute allergic response.

Before initiating lacosamide therapy, several safety considerations should be observed.

- Monitor cardiac conduction: obtain baseline ECG and repeat if symptoms arise. - Assess renal function: adjust dosing in severe impairment. - Evaluate hepatic status: monitor liver enzymes during treatment. - Avoid abrupt discontinuation: taper under medical supervision to prevent seizure rebound. - Caution in polytherapy: watch for additive CNS depression with other antiepileptics. - Store at ambient temperature: keep in original container, protect from moisture and light.

Lacosamide can interact with various medications, influencing efficacy or safety.

Major Interactions (Avoid): - Carbamazepine co‑administration: may lower lacosamide plasma levels. - Strong CYP3A4 inducers (e.g., rifampin): can reduce therapeutic effect. - Other sodium‑channel blockers (e.g., phenytoin): increase risk of cardiac conduction issues.

Moderate Interactions (Monitor Closely): - CYP2C19 inhibitors (e.g., fluconazole): may raise lacosamide exposure. - Drugs that prolong PR interval (e.g., verapamil): require ECG monitoring. - Alcohol consumption: may enhance central nervous system depression. - Concomitant use with antihistamines: possible additive sedation. - Co‑administration with opioids: monitor for increased respiratory depression.